Espino Y Sosa Salvador, Flores-Pliego Arturo, Espejel-Nuñez Aurora, Medina-Bastidas Diana, Vadillo-Ortega Felipe, Zaga-Clavellina Veronica, Estrada-Gutierrez Guadalupe
Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico.
Department of Immunobiochemistry, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico.
Int J Mol Sci. 2017 Jul 20;18(7):1448. doi: 10.3390/ijms18071448.
Preeclampsia is a severe pregnancy complication globally, characterized by poor placentation triggering vascular dysfunction. Matrix metalloproteinases (MMPs) exhibit proteolytic activity implicated in the efficiency of trophoblast invasion to the uterine wall, and a dysregulation of these enzymes has been linked to preeclampsia. A decrease in MMP-2 and MMP-9 interferes with the normal remodeling of spiral arteries at early pregnancy stages, leading to the initial pathophysiological changes observed in preeclampsia. Later in pregnancy, an elevation in MMP-2 and MMP-9 induces abnormal release of vasoactive factors conditioning hypertension. Although these two enzymes lead the scene, other MMPs like MMP-1 and MMP-14 seem to have a role in this pathology. This review gathers published recent evidence about the implications of different MMPs in preeclampsia, and the potential use of these enzymes as emergent biomarkers and biological therapeutic targets, focusing on studies involving human subjects.
子痫前期是一种全球范围内严重的妊娠并发症,其特征是胎盘形成不良引发血管功能障碍。基质金属蛋白酶(MMPs)具有蛋白水解活性,与滋养层细胞侵入子宫壁的效率有关,这些酶的失调与子痫前期有关。MMP-2和MMP-9的减少会干扰妊娠早期螺旋动脉的正常重塑,导致子痫前期最初观察到的病理生理变化。在妊娠后期,MMP-2和MMP-9的升高会诱导血管活性因子异常释放,从而引发高血压。尽管这两种酶起主要作用,但其他MMPs如MMP-1和MMP-14似乎也在这种病理过程中发挥作用。本综述收集了最近发表的关于不同MMPs在子痫前期中的影响以及这些酶作为新兴生物标志物和生物治疗靶点的潜在用途的证据,重点关注涉及人类受试者的研究。